大型患者 registry 中难治性类风湿关节炎成人的患病率与特征
研究在 Brigham and Women's Hospital 类风湿关节炎序贯研究(BRASS)registry 的 1581 例类风湿关节炎(RA)患者中应用 2021 年 EULAR 的难治性(D2T)RA 定义,估计 D2T-RA 患病率为每 100 人 14.4(95%CI:12.8,16.3),在 1021 例生物制剂/靶向合成 DMARD 经治者中为每 100 人 22.3(95%CI:19.9,25.0)。D2T-RA 与非 D2T-RA 匹配对照在人口学、合并症和 RA 疾病活动度上观察到若干差异。EULAR 各亚标准组合得到的 D2T-RA 患病率范围为每 100 人 0.6 至 17.5。
要点
- 在 1581 例 RA 患者中,D2T-RA 患病率为每 100 人 14.4(95%CI:12.8,16.3)。
- 在 1021 例生物制剂/靶向合成 DMARD 经治者中,D2T-RA 患病率为每 100 人 22.3(95%CI:19.9,25.0)。
- 不同 EULAR 亚标准组合下 D2T-RA 患病率范围为每 100 人 0.6 至 17.5。
核心结论
- EULAR 提出的 D2T-RA 定义可识别未达到治疗目标的 RA 患者,未来研究应探索这些患者的异质性并评估结局,以指导旨在开发更有效 RA 管理方案的研究设计。
研究设计与样本
- 研究使用 Brigham and Women's Hospital 类风湿关节炎序贯研究(BRASS)registry 的纵向数据,将符合 EULAR 定义的参与者归类为 D2T。
- 每例 D2T 患者按 2:1 匹配非 D2T-RA 对照,采用描述性分析评估特征差异,并用 Poisson 回归估计 D2T 患病率。
主要发现
- 在 1581 例 RA 参与者中,D2T-RA 患病率为每 100 人 14.4(95%CI:12.8,16.3)。
- 在 1021 例生物制剂/靶向合成 DMARD 经治者中,D2T-RA 患病率为每 100 人 22.3(95%CI:19.9,25.0)。
- D2T-RA 与非 D2T-RA 匹配对照在人口学、合并症和 RA 疾病活动度上观察到若干差异。
- 在 BRASS 全部参与者中,不同 EULAR 亚标准组合得到的 D2T-RA 患病率范围为每 100 人 0.6 至 17.5。
关键数值与推荐
- D2T 分类依据 2021 年 EULAR 工作组提出的 D2T-RA 定义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: An estimated 5-20% of patients with rheumatoid arthritis (RA) fail multiple treatments and are considered 'difficult-to-treat' (D2T), posing a substantial clinical challenge for rheumatologists. A European League Against Rheumatism (EULAR) task force proposed a definition of D2T-RA in 2021. We applied EULAR's D2T definition in a cohort of patients with established RA to assess prevalence, and we compared clinical characteristics of participants with D2T-RA with matched comparisons. METHODS: Data from the longitudinal Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) registry were used. Participants were classified as D2T if they met EULAR's definition. A comparison group of non-D2T-RA patients were matched 2:1 to every D2T patient, and differences in characteristics were evaluated in descriptive analyses. Prevalence rates of D2T were estimated using Poisson regression. RESULTS: We estimated the prevalence of D2T-RA to be 14.4 (95% CI: 12.8, 16.3) per 100 persons among 1581 participants with RA, and 22.3 (95% CI: 19.9, 25.0) per 100 persons among 1021 who were biologic/targeted synthetic DMARD experienced. We observed several differences in demographics, comorbidities and RA disease activity between D2T-RA and non-D2T-RA comparisons. Varying EULAR sub-criteria among all participants in BRASS resulted in a range of D2T-RA prevalence rates, from 0.6 to 17.5 per 100 persons. CONCLUSION: EULAR's proposed definition of D2T-RA identifies patients with RA who have not achieved treatment targets. Future research should explore heterogeneity in these patients and evaluate outcomes to inform the design of future studies aimed at developing more effective RA management protocols.
引用
- Paudel ML, Li R, Naik C, et al. Prevalence and characteristics of adults with difficult-to-treat rheumatoid arthritis in a large patient registry. Rheumatology (Oxford). 2025. PMID: 38837701. doi:10.1093/rheumatology/keae318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。